ArticleBlood cancer journal2013
(18)F-FDG-PET/CT imaging in an IL-6- and MYC-driven mouse model of human multiple myeloma affords objective evaluation of plasma cell tumor progression and therapeutic response to the proteasome inhibitor ixazomib.
Article in Blood cancer journal, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 33 citations in OpenAlex.
- Imaging Approaches in Cancer Biology.Cold Spring Harbor perspectives in medicine · 2024Review
- IL6Myc mouse is an immunocompetent model for the development of aggressive multiple myeloma.Haematologica · 2023Article
- Current and Future PET Imaging for Multiple Myeloma.Life (Basel, Switzerland) · 2023Review
- Article
- WDR26 and MTF2 are therapeutic targets in multiple myeloma.Journal of hematology & oncology · 2021Article
- [Frontiers in oncology · 2021Article
- Osteolytic disease in IL-6 and Myc dependent mouse model of human myeloma.Haematologica · 2020Article
- Article
- Prevention Is the Best Treatment: The Case for Understanding the Transition from Monoclonal Gammopathy of Undetermined Significance to Myeloma.International journal of molecular sciences · 2018Review
- Determining Glucose Metabolism Kinetics Using 18F-FDG Micro-PET/CT.Journal of visualized experiments : JoVE · 2017Article
- NEK2 Promotes Aerobic Glycolysis in Multiple Myeloma Through Regulating Splicing of Pyruvate Kinase.Journal of hematology & oncology · 2017Article
- Transgenic mouse model of IgMBlood cancer journal · 2016Article
- Exposure-safety-efficacy analysis of single-agent ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma: dose selection for a phase 3 maintenance study.Investigational new drugs · 2016Article
- Adoptive B-cell transfer mouse model of human myeloma.Leukemia · 2016Article
- Article
- KSHV-encoded vIL-6 collaborates with deregulated c-Myc to drive plasmablastic neoplasms in mice.Blood cancer journal · 2016Article
- Preclinical animal models of multiple myeloma.BoneKEy reports · 2016Article
- Regulation of glucose tolerance and sympathetic activity by MC4R signaling in the lateral hypothalamus.Diabetes · 2015Article
- Bruton tyrosine kinase is a therapeutic target in stem-like cells from multiple myeloma.Cancer research · 2015Article
- CDKN1A and FANCD2 are potential oncotargets in Burkitt lymphoma and multiple myeloma.Experimental hematology & oncology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 3 institutions in 1 country.
Funding
Abstract
(18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) and computed tomography (CT) are useful imaging modalities for evaluating tumor progression and treatment responses in genetically engineered mouse models of solid human cancers, but the potential of integrated FDG-PET/CT for assessing tumor development and new interventions in transgenic mouse models of human blood cancers such as multiple myeloma (MM) has not been demonstrated. Here we use BALB/c mice that contain the newly developed iMyc(ΔEμ) gene insertion and the widely expressed H2-L(d)-IL6 transgene to demonstrate that FDG-PET/CT affords an excellent research tool for assessing interleukin-6- and MYC-driven plasma cell tumor (PCT) development in a serial, reproducible and stage- and lesion-specific manner. We also show that FDG-PET/CT permits determination of objective drug responses in PCT-bearing mice treated with the investigational proteasome inhibitor ixazomib (MLN2238), the biologically active form of ixazomib citrate (MLN9708), that is currently in phase 3 clinical trials in MM. Overall survival of 5 of 6 ixazomib-treated mice doubled compared with mice left untreated. One outlier mouse presented with primary refractory disease. Our findings demonstrate the utility of FDG-PET/CT for preclinical MM research and suggest that this method will play an important role in the design and testing of new approaches to treat myeloma.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.